Biotechnology Regenerative Medicine Law In Russia.

1. Introduction

Regenerative medicine is an advanced branch of biotechnology that focuses on repairing, replacing, restoring, or regenerating damaged human cells, tissues, and organs. It uses scientific techniques such as stem-cell therapy, tissue engineering, cellular therapy, gene therapy, biomaterials, and biologically engineered products.

In Russia, regenerative medicine is regulated through a combination of federal legislation, healthcare regulations, biotechnology rules, pharmaceutical laws, medical licensing requirements, and judicial principles.

Unlike some jurisdictions, Russia does not have one comprehensive federal statute exclusively devoted to regenerative medicine. Instead, its principal regulatory framework includes:

Federal Law No. 180-FZ of 23 June 2016, On Biomedical Cell Products.

Federal Law No. 323-FZ of 21 November 2011, On the Fundamentals of Health Protection of Citizens in the Russian Federation.

Federal Law No. 61-FZ of 12 April 2010, On the Circulation of Medicines.

Federal Law No. 99-FZ of 4 May 2011, On Licensing Certain Types of Activities.

Government Resolution No. 1184 of 3 October 2018, concerning licensing the production of biomedical cell products.

Government Resolution No. 384 of 28 March 2024, concerning certain biomedical cell products manufactured individually for patients.

The most important legislation is Federal Law No. 180-FZ, which establishes the regulatory framework for the development, testing, registration, production, distribution, and clinical application of biomedical cell products.

Контур.Экстерн+3

2. Meaning and Scope of Regenerative Medicine under Russian Law

Regenerative medicine involves biological methods intended to restore normal physiological functions through cellular and tissue regeneration.

Its major applications include:

Stem-cell-based treatments.

Bone marrow and hematopoietic stem-cell transplantation.

Tissue engineering.

Regenerative skin treatment.

Cartilage and bone regeneration.

Cellular immunotherapy.

Gene-based regenerative treatments.

Biologically engineered tissue replacement.

Autologous and allogeneic cell therapies.

Russian law distinguishes between different categories of biological materials and therapeutic products.

An important distinction is that not every medical procedure involving cells is automatically regulated as a biomedical cell product under Law No. 180-FZ.

For example:

TechnologyPrincipal legal framework
Biomedical cell productsFederal Law No. 180-FZ
Medicinal productsFederal Law No. 61-FZ
Medical servicesFederal Law No. 323-FZ
Organ transplantationTransplantation legislation and healthcare law
Bone marrow transplantationHealthcare and transplantation regulations
Gene therapy medicinesRussian and Eurasian Economic Union pharmaceutical rules
Medical devices used in tissue engineeringMedical-device legislation

This classification is important because different authorization, manufacturing, safety, and clinical-testing requirements apply to different technologies.

Контур.Экстерн+2

3. Federal Law No. 180-FZ of 2016: Principal Legislation

Primary legislation

Federal Law No. 180-FZ, adopted on 23 June 2016, is the central statutory instrument governing biomedical cell products in Russia.

It entered into force on 1 January 2017.

The legislation regulates:

Development of biomedical cell products.

Preclinical research.

Clinical research.

Ethical examination.

State registration.

Manufacturing.

Quality control.

Distribution and application.

Storage and transportation.

Destruction of defective products.

Donation of biological material.

Compensation for injuries associated with cell products.

The law was substantially amended by Federal Law No. 466-FZ of 4 August 2023, with important amendments taking effect on 1 April 2024.

The amendments clarified product classification and introduced a specific framework for certain individualized biomedical cell products.

Контур.Экстерн+1

Important provisions

Section 1 – Scope of regulation

The law regulates the lifecycle of biomedical cell products, from development and preclinical testing to clinical use, storage, transportation, and destruction.

It also regulates biological-material donation for manufacturing such products.

However, it excludes certain activities, including ordinary medicinal-product development, medical devices, organ and tissue donation for transplantation, blood donation, and scientific or educational use of human cells and tissues.

Section 2 – Definitions

The legislation defines biomedical cell products as complexes consisting of cell lines and auxiliary substances, potentially combined with registered medicinal products, pharmaceutical substances, or medical devices.

It also distinguishes autologous and allogeneic biomedical cell products.

Autologous products use cells obtained from the same individual who receives the treatment.

Allogeneic products use cells obtained from another individual.

This distinction has implications for donor consent, biological traceability, manufacturing controls, and patient safety.

Section 3 – Fundamental principles

The law establishes important ethical principles:

Voluntary donation of biological material.

Gratuitous donation.

Protection of medical confidentiality.

Prohibition on the commercial buying and selling of biological material.

Prohibition on creating human embryos for the purpose of producing biomedical cell products.

Restrictions on using biological material obtained through interruption of embryonic or fetal development.

These principles establish an ethical foundation for Russian regenerative medicine.

Контур.Экстерн+1

4. Stem Cell Research and Regenerative Medicine

Stem-cell research is one of the most important areas of regenerative medicine.

Stem cells have the capacity to differentiate into specialized cell types and may potentially contribute to the restoration of damaged tissues.

Russia regulates the clinical application of relevant cell-based technologies through the biomedical cell product framework, transplantation rules, and general healthcare legislation.

Main legal requirements

A. Scientific justification

A regenerative treatment must have an appropriate scientific and medical basis. Researchers must establish the biological characteristics and intended therapeutic function of the product.

B. Preclinical testing

Before human clinical research, relevant safety and effectiveness questions must be examined through appropriate preclinical investigations.

C. Clinical authorization

Clinical investigations of biomedical cell products require authorization under the applicable provisions of Law No. 180-FZ.

D. Ethical assessment

Research must satisfy applicable ethical requirements, including protection of research participants and informed consent.

E. Product safety

Manufacturers and medical organizations must comply with applicable quality, manufacturing, and handling requirements.

A clinic cannot lawfully avoid the regulatory framework merely by describing an experimental stem-cell procedure as an innovative or personalized treatment.

Consultant Plus+2

5. Regulation of Autologous and Allogeneic Cell Therapies

Russian law recognizes two important categories of cell-based treatment.

A. Autologous regenerative medicine

Autologous treatment uses biological material obtained from the patient who receives the treatment.

Examples include:

Patient-derived stem-cell therapies.

Autologous cellular tissue repair.

Certain cell-based reconstructive treatments.

Individualized cellular products.

The main legal concerns include:

Identification of the donor-patient.

Collection and processing of biological material.

Prevention of contamination.

Quality assurance.

Traceability.

Medical justification.

Informed consent.

B. Allogeneic regenerative medicine

Allogeneic treatment uses biological material from one individual for another individual.

Examples include certain donor-derived stem-cell products and other cellular therapeutic products.

Additional legal concerns arise regarding:

Donor eligibility.

Voluntary donation.

Biological-material testing.

Infectious disease risks.

Donor confidentiality.

Compatibility and immunological safety.

Traceability from donor to recipient.

The distinction is especially important in determining the applicable regulatory pathway and the allocation of responsibilities between manufacturers, laboratories, and medical organizations.

Контур.Экстерн+1

6. Preclinical Research and Clinical Trials

Clinical research is essential to establishing whether a regenerative treatment is sufficiently safe and effective for human use.

Under Federal Law No. 180-FZ, biomedical cell products are subject to a structured research and authorization system.

A. Preclinical research

Preclinical studies examine the biological characteristics and potential risks of a product before it is administered to human participants.

They may involve:

Animal models.

Cellular models.

Immunological investigations.

Toxicological studies.

Pharmacological investigations.

Microbiological testing.

Evaluation of the product's mechanism of action.

The purpose is to establish evidence concerning product quality, safety, and potential effectiveness.

B. Clinical trials

Articles 16–17 and 28 of Law No. 180-FZ establish the authorization and organizational framework for clinical investigations.

Clinical investigations examine:

Safety and tolerability.

Adverse reactions.

Therapeutic effectiveness.

Appropriate dosage and administration.

Interactions with other products.

Long-term clinical outcomes.

Clinical investigations must comply with applicable good clinical practice requirements.

C. Ethical review

Ethical review is particularly important where human participants receive experimental cellular treatments.

The principal issues include:

Voluntary participation.

Informed consent.

Disclosure of potential risks.

Protection of vulnerable patients.

Confidentiality of medical information.

Appropriate management of adverse events.

A patient must not be misled into believing that an experimental regenerative procedure is an established and proven treatment.

Consultant Plus+2

7. State Registration and Marketing Authorization

State registration is a fundamental requirement for the ordinary commercial circulation of biomedical cell products.

Under Article 8 of Federal Law No. 180-FZ, manufacturing, distribution, application, storage, and transportation of products generally require registration.

The legislation provides a special exception for certain biomedical cell products manufactured specifically for an individual patient directly within the medical organization where the product is applied.

Registration requirements

An applicant generally needs to provide:

Product specifications.

Manufacturing technology.

Preclinical research documentation.

Clinical research documentation.

Quality-control information.

Safety evidence.

Effectiveness evidence.

Relevant expert assessments.

The regulatory authority examines the submitted information before deciding whether registration is justified.

Importance of the 2024 amendments

Federal Law No. 466-FZ introduced a more specific regulatory distinction between biomedical cell products, transplantation objects, and high-technology medicinal products, including gene therapy medicines.

This distinction is important because a gene therapy medicine cannot simply be treated as an ordinary biomedical cell product.

The amended framework also introduced Article 32.1, which deals with individualized biomedical cell products manufactured directly in the medical organization for a particular patient.

Government Resolution No. 384 of 28 March 2024 provides additional rules for this individualized pathway.

Importantly, this is not a general exemption from safety regulation. Product quality, medical justification, manufacturing controls, and patient protection remain relevant.

Контур.Экстерн+2

8. Licensing and Regulation of Manufacturing Facilities

Manufacturing biomedical cell products requires compliance with specific licensing requirements.

The main legislative framework includes:

Federal Law No. 99-FZ of 2011.

Federal Law No. 180-FZ of 2016.

Government Resolution No. 1184 of 3 October 2018.

The licensing system is intended to ensure that manufacturing organizations possess appropriate facilities, equipment, qualified personnel, and quality-control systems.

Major compliance obligations

1. Qualified personnel

Manufacturing activities must be conducted by appropriately trained and qualified personnel.

2. Laboratory standards

Facilities must maintain appropriate laboratory conditions to minimize contamination and preserve product integrity.

3. Quality management

Manufacturers must establish documented quality-control and quality-assurance procedures.

4. Manufacturing documentation

Manufacturing processes must be properly documented and traceable.

5. Storage and transportation

Cellular materials must be stored and transported under conditions that maintain their quality and safety.

6. Regulatory inspections

The competent authorities may inspect regulated manufacturing activities and take enforcement action where legal requirements are violated.

Roszdravnadzor plays an important supervisory role in the biomedical cell product sector.

roszdravnadzor.gov.ru+2

9. Individualized Regenerative Medicine and Hospital Manufacturing

One important development in Russian biotechnology law is the regulation of individualized biomedical cell products.

Individualized treatment may involve collecting cells from a patient, processing them within a medical organization, and administering the resulting product to that same patient.

This is particularly relevant to personalized regenerative medicine.

Before the 2024 reforms, the legal treatment of hospital-manufactured cellular products created regulatory uncertainty.

The amendments to Law No. 180-FZ introduced Article 32.1 and a specific pathway for products manufactured for an individual patient directly in the medical organization where they are used.

Important legal considerations

The product must meet the statutory definition.

Manufacturing must follow the applicable legal requirements.

Appropriate quality controls must be maintained.

The product must be intended for the identified patient.

The medical organization must comply with applicable clinical and professional obligations.

Defective and falsified products remain subject to regulatory action.

This development supports personalized treatment while maintaining public-health safeguards.

Контур.Экстерн+1

10. Patient Rights and Informed Consent

Patient protection is a central feature of regenerative medicine regulation.

Federal Law No. 323-FZ establishes the general legal framework for healthcare rights and medical responsibilities.

Patients undergoing regenerative treatments have important rights, including:

The right to information about their medical condition.

The right to receive information about proposed treatment.

The right to informed voluntary consent.

The right to refuse medical intervention, subject to applicable legal exceptions.

The right to medical confidentiality.

The right to appropriate medical care.

The right to seek compensation where legally established harm has occurred.

Informed consent in stem-cell treatment

Consent should explain:

The nature of the cellular procedure.

Whether the treatment is experimental.

Its established and unestablished benefits.

Potential adverse reactions.

Available alternatives.

The scientific uncertainty involved.

The expected treatment process.

A clinic that promises guaranteed regeneration, complete organ restoration, or a scientifically unproven cure may face regulatory and civil liability.

Informed consent does not automatically excuse medical negligence, defective products, or misleading representations.

edu.rosminzdrav.ru+1

11. Product Liability and Medical Negligence

Regenerative medicine creates distinctive liability problems because cellular products may have complex biological characteristics.

Potential injuries include:

Infection.

Immune reactions.

Abnormal cell proliferation.

Tissue damage.

Contamination.

Unexpected biological reactions.

Failure of the intended therapeutic outcome.

Article 40 of Federal Law No. 180-FZ addresses compensation for harm caused by biomedical cell products.

Its framework distinguishes between different causes of injury.

For example:

A. Defective biomedical cell products

Where harm is caused by a defective biomedical cell product or inaccurate information in its instructions, the statutory liability provisions may apply.

B. Incorrect application

Where the medical organization applies a product contrary to its instructions and that violation causes injury, the organization may be required to compensate the patient.

C. Medical negligence

Where a healthcare professional fails to meet the applicable standard of care, liability may also arise under general Russian civil and healthcare law.

D. Misleading advertising

A clinic making unsupported claims about the effectiveness of regenerative treatments may face consequences under applicable advertising, consumer-protection, and healthcare legislation.

The legal analysis must establish causation, the applicable duty, the nature of the defect or professional breach, and the relevant statutory conditions.

Контур.Экстерн+1

12. Ethical Regulation of Regenerative Medicine

Ethics is particularly important because regenerative medicine can involve embryonic material, stem cells, genetic modification, and experimental interventions.

Federal Law No. 180-FZ establishes several express ethical restrictions.

A. Protection of human embryos

The legislation prohibits creating human embryos for the purpose of producing biomedical cell products.

B. Voluntary donation

Biological-material donation must be voluntary and gratuitous.

C. Protection against exploitation

The prohibition on commercial buying and selling of biological material is intended to reduce exploitation and unethical procurement.

D. Confidentiality

Donor and patient information must be protected under applicable confidentiality and personal-data legislation.

E. Research-participant protection

Clinical research must respect informed consent, appropriate ethical review, and safety requirements.

These principles are especially significant in research involving embryonic stem cells, induced pluripotent stem cells, and genetically modified cellular materials.

Контур.Экстерн+1

13. Regulation of Gene Therapy and Tissue Engineering

Regenerative medicine increasingly overlaps with gene therapy and tissue engineering.

However, Russian law does not classify every gene-based treatment as a biomedical cell product.

Following the 2023 amendments, high-technology medicinal products, including gene therapy medicinal products subject to the relevant pharmaceutical authorization framework, are distinguished from biomedical cell products.

This distinction affects:

Product classification.

Manufacturing authorization.

Clinical investigations.

Registration.

Safety monitoring.

Commercial distribution.

Liability.

Tissue engineering may similarly involve multiple legal categories, depending on whether the technology is classified as a cellular product, medicinal product, medical device, or transplantation object.

Therefore, classification must be undertaken before choosing the authorization pathway.

Контур.Экстерн+2

14. Important Russian Court Cases on Regenerative Medicine

Russian reported judicial decisions specifically interpreting Federal Law No. 180-FZ remain relatively limited. Nevertheless, several important judgments concerning cellular technologies, medical licensing, and regulatory supervision provide useful legal principles.

Case 1. Institute of Human Stem Cells v. Roszdravnadzor (2016–2017)

Directly relevant cellular-technology precedent

Court: Moscow Arbitration Court system.

Case number: A40-58903/2016.

Important decisions:

Moscow Arbitration Court: 22 July 2016.

Ninth Arbitration Court of Appeal: 31 October 2016.

Moscow District Arbitration Court: 21 February 2017, No. F05-244/17.

Supreme Court of the Russian Federation: 13 June 2017, No. 305-KG17-6103.

Facts:

The Institute of Human Stem Cells possessed a medical licence issued in 2012. The licence included the service described as the application of cellular technologies in providing high-technology medical assistance.

Roszdravnadzor subsequently required the institution to bring its licence into conformity with the updated list of licensed medical services.

The institute challenged the regulatory requirement.

Legal issue:

Whether an existing medical licence containing a previously recognized description of cellular-technology services had to be reissued following changes in the applicable licensing framework.

Judicial development:

The Ninth Arbitration Court of Appeal initially ruled in favour of the institute and invalidated the regulatory requirement.

However, the Moscow District Arbitration Court subsequently reversed that appellate outcome, and the Supreme Court refused to transfer the institute's complaint for consideration by its Judicial Chamber.

Legal significance:

The dispute demonstrates that:

Cellular technology does not automatically create an exemption from medical licensing.

Medical licences must comply with the applicable regulatory classification.

Healthcare regulators can require licences to be brought into conformity with updated legal requirements.

The use of innovative biotechnology does not remove ordinary medical regulatory obligations.

Relevance to regenerative medicine: This case is particularly important for stem-cell clinics, cellular-therapy institutions, and organizations providing regenerative medical services.

medvestnik.ru+2

Case 2. Institute of Human Stem Cells v. Russian Constitutional Court (2017)

Court: Constitutional Court of the Russian Federation.

Decision: 23 November 2017.

Case number: 2542-O.

Facts:

The institute challenged the constitutionality of Article 22(6.1) of Federal Law No. 99-FZ on licensing.

It argued that requiring the reissuance of its licence following changes to the list of licensed medical services interfered with its constitutional rights to conduct business.

Legal issue:

Whether the statutory requirement to update an existing licence violated constitutional protections concerning economic freedom and legal certainty.

Decision:

The Constitutional Court refused to accept the complaint for consideration.

It explained that the federal legislature has authority to establish licensing conditions and additional requirements for activities involving public health and safety.

The Court also emphasized that the licensing requirement was intended to prevent harm to citizens' rights, legitimate interests, life, and health.

It observed that the institute had not established that it had applied for licence reissuance and received a refusal from the competent authority.

Legal principles:

Economic freedom is subject to lawful public-health regulation.

Medical licensing requirements may be updated.

Innovative medical services remain subject to licensing legislation.

Regulatory requirements designed to protect patients are not automatically unconstitutional.

Relevance to regenerative medicine: This decision provides an important constitutional foundation for regulating stem-cell clinics, tissue-engineering facilities, and regenerative medical institutions.

Контур.Экстерн+1

Case 3. Federal Law No. 180-FZ and the statutory framework for biomedical cell products

Legislation: Federal Law No. 180-FZ of 23 June 2016.

This is a statutory authority rather than an individual judicial judgment.

It is nevertheless central to regenerative medicine disputes because it establishes the legal requirements against which regulatory and judicial decisions must be assessed.

Its principal areas of relevance include:

Product registration.

Manufacturing standards.

Clinical investigation.

Biological-material donation.

Product quality.

Patient safety.

Product-related compensation.

It is particularly important in disputes involving unauthorized cellular products, manufacturing deficiencies, and patient injuries.

Контур.Экстерн+1

Case-law assessment

The two Institute of Human Stem Cells proceedings are especially useful because they concern actual cellular technologies and medical licensing.

However, they should not be misrepresented as judgments interpreting the entire 2016 biomedical cell product legislation. Both disputes arose from licensing events preceding the operation of the principal framework under Law No. 180-FZ.

The available verified decisions do not establish a comprehensive body of Supreme Court precedent specifically interpreting every provision of that law.

15. Regulatory Authorities Responsible for Regenerative Medicine

Several Russian governmental institutions have responsibilities relevant to regenerative medicine.

AuthorityPrincipal responsibility
Ministry of Health of RussiaHealthcare policy and biomedical cell product registration
RoszdravnadzorHealthcare supervision and regulatory enforcement
Government of RussiaAdoption of implementing regulations
Federal licensing authoritiesLicensing regulated manufacturing and medical activities
Ethics committeesEthical assessment of relevant clinical investigations
Medical organizationsLawful treatment, patient safety, and clinical documentation

Roszdravnadzor has a particularly important role in supervising the circulation of biomedical cell products.

Its regulatory functions include monitoring compliance, inspecting regulated activities, and addressing defective or falsified products.

16reg.roszdravnadzor.ru+1

16. Cross-Border Regenerative Medicine and International Cooperation

Regenerative medicine increasingly involves international scientific collaboration.

Russian organizations may encounter international legal questions involving:

Importation of cellular materials.

Exportation of biomedical cell products.

International clinical investigations.

Foreign donor biological material.

Cross-border biotechnology research.

International pharmaceutical manufacturing.

Recognition of foreign clinical research.

Transfer of genetic and biological information.

Federal Law No. 180-FZ addresses certain international aspects of biomedical cell product circulation.

For example, Article 28 provides for recognition of foreign clinical investigation results in accordance with applicable international agreements or, in their absence, the principle of reciprocity.

However, recognition of foreign research does not automatically authorize commercial distribution or clinical application in Russia.

Other applicable Russian legislation and Eurasian Economic Union requirements must also be considered.

Consultant Plus+1

17. Major Legal Challenges in Russian Regenerative Medicine

Despite the development of a specific statutory framework, several legal challenges remain.

A. Classification uncertainty

A regenerative treatment may involve cells, tissues, biological materials, medicines, or medical devices.

Determining its correct legal classification can be difficult.

B. Experimental treatment

Patients may receive procedures whose therapeutic effectiveness has not been adequately established.

This creates difficulties concerning informed consent, clinical authorization, and medical responsibility.

C. Individualized manufacturing

Personalized cell products create challenges involving manufacturing consistency, quality control, and traceability.

D. Long-term safety

Some cellular interventions may create risks that become apparent only after extended periods.

E. Commercial exploitation

Commercial clinics may advertise regenerative treatments using exaggerated or scientifically unsupported claims.

F. Liability allocation

It can be difficult to determine whether responsibility lies with the cell-product manufacturer, laboratory, medical organization, or treating professional.

G. Gene-editing technologies

New technologies involving genetically modified cells raise additional questions about product classification, clinical safety, and long-term monitoring.

H. Regulatory fragmentation

The division of regenerative medicine between healthcare, pharmaceutical, transplantation, biotechnology, and medical-device legislation can create overlapping regulatory requirements.

PubMed Central (PMC)+2

18. Suggestions for Legal and Regulatory Reform

Further development of Russian regenerative medicine law could benefit from the following reforms:

1. Comprehensive legislation: Develop a clearer consolidated regulatory framework for regenerative medicine.

2. Stem-cell treatment standards: Establish more detailed standards for different categories of stem-cell interventions.

3. Clinical trial transparency: Improve public access to information about authorized regenerative medicine investigations.

4. Patient compensation: Strengthen mechanisms for compensation where injuries result from defective cellular products or negligent medical treatment.

5. Long-term monitoring: Develop appropriate long-term safety-monitoring systems.

6. Biological traceability: Strengthen donor-to-recipient traceability and biological-material identification.

7. Advertising regulation: Improve enforcement against misleading claims about experimental regenerative treatments.

8. Personalized medicine: Clarify regulatory requirements for individualized manufacturing and hospital-based cellular products.

9. Gene therapy coordination: Improve coordination between biomedical cell product legislation and pharmaceutical regulation.

10. International harmonization: Promote compatibility with internationally recognized clinical research and manufacturing standards.

19. Conclusion

Regenerative medicine in Russia is governed by an evolving combination of biotechnology legislation, pharmaceutical regulation, healthcare law, medical licensing, and patient-protection requirements.

Federal Law No. 180-FZ of 2016 is the principal legislation for biomedical cell products. Its 2023 amendments, effective in important respects from April 2024, further clarified product classification and introduced a specific framework for certain individualized cellular treatments.

Federal Law No. 323-FZ provides the broader healthcare framework, while Federal Law No. 61-FZ regulates medicinal products, including relevant high-technology medicines.

The Institute of Human Stem Cells litigation, particularly Arbitration Case No. A40-58903/2016 and Constitutional Court Decision No. 2542-O of 2017, illustrates the importance of medical licensing and regulatory compliance when cellular technologies are used in clinical practice.

The central legal principle is that scientific innovation does not eliminate regulatory responsibility. Regenerative medicine must operate within a framework that protects patients, ensures product quality, maintains ethical standards, and establishes accountability for medical injuries.

20. Important Legal Sources and Research References

Legal sourceSubject
Federal Law No. 180-FZ (2016)Biomedical cell products
Federal Law No. 323-FZ (2011)Citizens' healthcare rights
Federal Law No. 61-FZ (2010)Medicinal products
Federal Law No. 99-FZ (2011)Licensing
Government Resolution No. 1184 (2018)Biomedical cell product manufacturing licences
Government Resolution No. 384 (2024)Individualized biomedical cell products
Constitutional Court Decision No. 2542-O (2017)Licensing of cellular technologies
Supreme Court Decision No. 305-KG17-6103 (2017)Institute of Human Stem Cells litigation

Useful research materials:

Federal Law No. 180-FZ – Biomedical Cell Products.

Federal Law No. 323-FZ – Healthcare Legislation.

Constitutional Court Decision No. 2542-O.

Supreme Court Decision No. 305-KG17-6103.

Almost 40 Years of Tissue Engineering in Russia: Where Are We Now?.

Transforming the Legal Regulation of Regenerative Medicine: Conflict of Laws and Resolution Mechanisms (2026).

Academic note: This explanation distinguishes binding legislation and verified judicial decisions from scholarly analysis and proposed reforms. It is intended for legal research and does not replace advice on a particular Russian regulatory or clinical matter.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT